Stoke Therapeutics (STOK) Return on Sales (2022 - 2026)

Stoke Therapeutics' Return on Sales history runs 5 years deep, the most recent figure standing at 0.08% for Q1 2026.

• On a quarterly basis, Return on Sales fell 9.0% year-over-year to 0.08% in Q1 2026; TTM through Mar 2026 was 0.05%, a 6.0% decrease from a year earlier, with the FY2025 full-year figure at 0.01%, up 2.0% from the prior year.
• Return on Sales advanced to 0.08% in Q1 2026 per STOK's latest filing, from 0.45% in the prior quarter.
• Across five years, Return on Sales topped out at 0.01% in Q1 2025 and bottomed at 0.58% in Q4 2023.
• The 5-year median for Return on Sales is 0.08% (2026), against an average of 0.13%.
• Across the five-year window, Return on Sales jumped 57 bps in 2024 and sank 44 bps in 2025, its largest moves.
• Year by year, Return on Sales stood at 0.38% in 2022, then plunged by 52 bps to 0.58% in 2023, then jumped by 99 bps to 0.01% in 2024, then tumbled by 6731 bps to 0.45% in 2025, then jumped by 82 bps to 0.08% in 2026.
• Per Business Quant, the three latest STOK Return on Sales figures stand at 0.08% (Q1 2026), 0.45% (Q4 2025), and 0.04% (Q3 2025).